8,665 Shares in TransMedics Group, Inc. (NASDAQ:TMDX) Bought by Values First Advisors Inc.

Values First Advisors Inc. acquired a new stake in TransMedics Group, Inc. (NASDAQ:TMDX) in the fourth quarter, HoldingsChannel reports. The institutional investor acquired 8,665 shares of the company’s stock, valued at approximately $684,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in TMDX. Harbour Capital Advisors LLC boosted its holdings in TransMedics Group by 1.7% during the fourth quarter. Harbour Capital Advisors LLC now owns 8,371 shares of the company’s stock worth $627,000 after buying an additional 140 shares in the last quarter. First Horizon Advisors Inc. lifted its position in shares of TransMedics Group by 45.1% in the 1st quarter. First Horizon Advisors Inc. now owns 544 shares of the company’s stock valued at $41,000 after acquiring an additional 169 shares in the last quarter. Belpointe Asset Management LLC lifted its position in shares of TransMedics Group by 51.6% in the 1st quarter. Belpointe Asset Management LLC now owns 558 shares of the company’s stock valued at $42,000 after acquiring an additional 190 shares in the last quarter. Cetera Investment Advisers lifted its position in shares of TransMedics Group by 2.7% in the 2nd quarter. Cetera Investment Advisers now owns 7,350 shares of the company’s stock valued at $617,000 after acquiring an additional 196 shares in the last quarter. Finally, RiverPark Advisors LLC lifted its position in shares of TransMedics Group by 19.5% in the 4th quarter. RiverPark Advisors LLC now owns 1,319 shares of the company’s stock valued at $104,000 after acquiring an additional 215 shares in the last quarter. 99.67% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at TransMedics Group

In related news, CFO Stephen Gordon sold 15,000 shares of TransMedics Group stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $77.07, for a total transaction of $1,156,050.00. Following the completion of the transaction, the chief financial officer now directly owns 13,075 shares of the company’s stock, valued at approximately $1,007,690.25. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other TransMedics Group news, CFO Stephen Gordon sold 15,000 shares of the business’s stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $77.07, for a total value of $1,156,050.00. Following the completion of the transaction, the chief financial officer now directly owns 13,075 shares of the company’s stock, valued at $1,007,690.25. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Tamer I. Khayal sold 10,000 shares of the business’s stock in a transaction dated Tuesday, January 16th. The stock was sold at an average price of $80.41, for a total transaction of $804,100.00. Following the completion of the transaction, the insider now directly owns 14,375 shares of the company’s stock, valued at $1,155,893.75. The disclosure for this sale can be found here. Insiders sold 92,949 shares of company stock valued at $7,710,719 in the last ninety days. Insiders own 6.70% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently commented on TMDX. JPMorgan Chase & Co. upped their price target on shares of TransMedics Group from $87.00 to $105.00 and gave the company an “overweight” rating in a research report on Tuesday, February 27th. Morgan Stanley increased their target price on shares of TransMedics Group from $75.00 to $95.00 and gave the stock an “equal weight” rating in a research report on Wednesday, February 28th. Oppenheimer increased their target price on shares of TransMedics Group from $92.00 to $105.00 and gave the stock an “outperform” rating in a research report on Tuesday, February 27th. Finally, Piper Sandler initiated coverage on shares of TransMedics Group in a research report on Thursday. They issued an “overweight” rating and a $95.00 target price for the company. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $102.00.

TransMedics Group Stock Down 0.2 %

TMDX stock traded down $0.18 during trading on Friday, hitting $73.94. 876,931 shares of the stock traded hands, compared to its average volume of 700,890. TransMedics Group, Inc. has a one year low of $36.42 and a one year high of $99.63. The company has a 50 day simple moving average of $83.45 and a 200 day simple moving average of $70.01. The company has a current ratio of 9.30, a quick ratio of 8.49 and a debt-to-equity ratio of 3.69.

TransMedics Group (NASDAQ:TMDX) last announced its quarterly earnings results on Monday, February 26th. The company reported $0.12 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.22. TransMedics Group had a negative net margin of 10.36% and a negative return on equity of 2.35%. The firm had revenue of $81.20 million during the quarter, compared to the consensus estimate of $68.49 million. During the same period last year, the firm posted ($0.21) EPS. The firm’s quarterly revenue was up 158.6% on a year-over-year basis. On average, equities research analysts expect that TransMedics Group, Inc. will post -0.22 EPS for the current year.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.